Background: The natural history of ulcerative colitis (UC) after liver transplantation (LT) for primary sclerosing cholangitis (PSC) remains ill defined.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a rare progressive cholestatic liver disease with presumed autoimmune etiology that is characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. [1] [2] [3] [4] [5] [6] [7] There is a strong association between PSC and inflammatory bowel diseases (IBDs), particularly ulcerative colitis (UC). About 60% to 90% of patients with PSC are found to have concurrent UC; however, less than 10% of patients with UC have PSC. [8] [9] [10] Although the extent and severity of UC rarely affects the natural course of PSC, the presence of PSC may change the histological features and clinical phenotype of IBD. Patients with coexisting PSC/UC have a higher prevalence of extensive colitis (albeit mild or asymptomatic), rectal sparing, backwash ileitis, and colon cancer. The overall mortality in these cases is worse than in those without concomitant PSC. [11] [12] [13] [14] [15] [16] Since there is no effective treatment to stop disease progression in PSC, many cases eventually lead to end-stage liver disease for which liver transplantation (LT) is the only available curative therapy. Five-year survival rates of 80% to 85% have been reported after LT for PSC. [17] [18] [19] [20] [21] [22] [23] [24] Since immunosuppressive agents such as steroids, cyclosporine, and azathioprine are routinely used after LT, it is expected that UC should run a quiescent or at least milder course after LT. [25] [26] [27] This expectation seems even more logical after the introduction of much more potent immunosuppressive agents such as mycophenolate mofetil (MMF) and tacrolimus.
Several studies have focused on the course of IBD after LT. These studies found conflicting results. Some studies revealed an improved or unchanged course, 26, 27, 35, 36, 40, 41 whereas others demonstrated increased exacerbations of IBD after LT. 25, [29] [30] [31] [32] [33] [34] 38, 42, 43 Having a clear insight into the influence of LT on the disease activity of UC in patients with PSC/ UC can affect our approach to these cases both before and after LT. 26 Therefore, we evaluated the course of UC before and after LT in a large number of patients with prolonged followup transplanted for PSC.
PATIENTS AND METHODS

Patients
After gaining study approval by the academic ethics committee of the Shiraz University of Medical Sciences, the prospectively maintained database, containing accrued information on all patients who underwent LT at the Shiraz University of Medical Sciences, Namazi Hospital, Shiraz, Iran, was reviewed. Patients older than 18 years, presence of UC before LT, and presence of PSC as the cause of LT were included in this retrospective study. Patients with Crohn's disease (CD), indeterminate colitis, lack of at least 6 months of follow-up after LT, and lack of adequate clinical follow-up and phone accessibility were excluded from the study.
Out of 2766 patients who received LTs in our center between 1993 and 2014, 301 patients who received LTs due to PSC and had adequate clinic follow-up and on-phone accessibility were identified. Of the 301 patients, 134 (44.6%) patients had PSC without concurrent IBD and 167 (55.4%) patients had concomitant PSC and IBD. Cases with PSC alone were excluded. Out of 167 patients with concomitant PSC and IBD, 160 (95.8%) had UC and 7 (4.2%) had CD. Patients with CD were excluded. Furthermore, 3 patients with colectomy done before LT and 5 more cases with de novo IBD (whose diseases were diagnosed for the first time after LT) were excluded from the study. Finally, 152 patients with PSC/UC were included in this study.
Demographic and clinical data extracted from transplant charts for each patient included sex, age at transplant, length of follow-up, age at diagnosis of PSC, age at diagnosis of UC, smoking status (more than 7 cigarettes per week) and alcohol consumption (more than 2 drinks per day) post-LT and pre-LT, family history of PSC or IBD, method of diagnosis of PSC, medications used for UC before and after LT, posttransplant immunosuppressive medications, model for end-stage liver disease (MELD) score and Child's class at LT, body weight at LT, transplant type, and the presence or number of rejection episodes. The diagnosis of PSC was established by compatible explant pathology, liver biopsy done before LT, and/or imaging studies. The onset of PSC was defined as the time of diagnosis before LT. Diagnosis of UC was established by clinical history followed by colonoscopy and compatible pathology. The onset of IBD was considered as the time of symptomatic presentation or endoscopic confirmation, whichever was earlier. Phone calls were made to all patients to acquire the missing information and, more importantly, to complete the colitis severity score sheet.
The primary outcome of interest was the activity of UC before and after LT. Two different scoring systems were used to evaluate the activity of UC before and after LT. In the first system, a modified form of classification reported originally by Befeler et al, 35 the patients were categorized according to their treatment requirements for most severe UC activity both before and after LT as follows: (1) quiescent disease: the absence of diarrhea, blood in the stool, rectal symptoms, abdominal pain, or loss of functional activity as a result of IBD; (2) disease requiring aminosalicylates (5-aminosalicylic acid ; mesalamine or sulfasalazine) to control symptoms; (3) flares of IBD requiring increased doses of oral prednisone or azathioprine to control disease activity; (4) flares of IBD requiring intravenous steroids to control disease activity; and (5) disease activity refractory to medical therapy resulting in surgery. The second was a clinical scoring system, namely the simple clinical colitis activity index, 47 in which the bowel frequency during the day and at night, presence of blood in the stool, urgency of defecation, general well-being, and extracolonic features were single components that patients received appropriate scores for. Finally, cases with either no change or improvement in disease activity according to the models already described above were compared as a single group with patients with any aggravation of their disease activity.
The standard immunosuppressive regimen used after LT consisted of a corticosteroid (with active tapering on follow-up), a calcineurin inhibitor (cyclosporine or tacrolimus), and an antimetabolite (MMF or, rarely, azathioprine). In patients with hepatocellular carcinoma or any contraindication to calcineurin inhibitors, sirolimus was used as a surrogate. The use of a specific drug was defined as a minimum of 3-month medication during the first 6 months after transplantation.
Statistical Methods
Statistical analysis performed by Pearson's chi-square test, t test, and univariate and multivariate logistic regression analyses for risk factor assessment. P values of 0.05 or less were considered statistically significant. All statistical analyses were performed with SPSS version 19.0 (IBM, Armonk, NY).
RESULTS
Baseline Characteristics
Out of 152 patients with PSC/UC who were included into the present study, 99 (65.1%) were male and 53 (34.9%) were female. The mean age at transplantation was 35 years (range, 18-68 years). The mean duration of patients' follow-up (considered as "duration of LT" or "duration after LT" in the rest of text) after LT was 47.7 6 33.5 months (range, 6-147 months). The mean age at the onset of UC was 27 years (range, 3-62 years), whereas the mean age at diagnosis of PSC was 29 years (range, 8-62 years). The mean duration of UC and PSC before LT was 99 (range, 3-336 months) and 71 months (range, 4-216 months), respectively. The demographics and clinical features of patients have been summarized in Table 1 . Seven (4.6%) cases received LT from living donors and 145 (95.4%) patients received livers from deceased donors. Out of 7 (4.6%) patients who underwent colectomy after LT, 5 (71.4%) were because of poorly controlled disease activity and 2 (28.6%) cases were due to existing colorectal cancer or dysplasia detected in post-LT surveillance. There was no significant association between colorectal cancer or dysplasia and ursodeoxycholic acid use after LT (P ¼ 0.83). The mean body weight at LT was 65 6 10.7 kg (range, 40-91 kg).
UC Disease Activity Before and After LT according to the Simple Clinical Colitis Activity Index Model
There was a significant difference between the simple clinical colitis activity index score before and after LT (P , 0.001). The mean activity index score was 7.0 6 4.47 before LT and 1.13 6 2.85 after LT. The simple clinical colitis activity index scores did not change in 24 (15.8%) patients before and after LT, decreased in 119 (78.3%), and increased in 9 (5.9%) patients after LT (Fig. 1) .
There was no significant difference found between patients with the same or diminished activity scores as a single group, and those with increased scores after LT in terms of male sex, smoking, type of surgery, living or deceased donor transplantation, occurrence of post-LT rejections, use of ursodeoxycholic acid, body weight at LT, post-LT immunosuppressive agents including sirolimus, and antithymocyte globulin (P . (Table 2) . Although there was no significant difference between groups based on medications used for IBD control before LT (P ¼ 0.18), a significant difference existed after LT (P , 0.001).
UC Disease Activity Before and After LT according to the Treatment Requirement Model
The activity of UC before LT was as follows: 8 patients (5.3%) had quiescent disease, 79 (52%) had disease controlled only with 5-ASAs, 48 (31.6%) had flare-ups mandating use of other agents such as oral steroids or azathioprine to control disease activity, and 17 (11.2%) had to be admitted and receive intravenous steroids due to severe flare-ups. By contrast, after LT, 17 patients (11.2%) had quiescent UC, 127 (83.6%) used only 5-ASAs, 3 (2%) had to use other agents rather than 5-ASAs to keep disease under control, and 5 patients (3.3%) had colectomy due to poorly controlled UC activity. Comparing UC activity before and after LT revealed that 71 (46.7%) patients required no change in their specific treatment before and after LT, 69 (45.4%) experienced some tapering in their treatments, and 12 (7.9%) had to use more aggressive treatment options after LT due to disease exacerbations (Fig. 2) . No statistically significant difference could be found in patients with no change or improvement in disease activity, as a single group, and those with aggravated UC clinical course after LT in terms of male sex, type of surgery, living or deceased donor transplantation, occurrence of post-LT rejections, use of ursodeoxycholic acid, and post-LT immunosuppressive agents including tacrolimus, sirolimus, and antithymocyte globulin (P . (Table 4 ). There was a significant difference between groups considering medications used for IBD management both before (P , 0.001) and after (P , 0.001) transplantation.
Risk Factors Assessment
All significant univariate variables were included in the multiple logistic regression analysis. In the simple clinical colitis activity index model, multiple logistic regression analysis demonstrated that cyclosporine exposure after LT (OR ¼ 0.14; 95% CI, 0.015-0.79, P ¼ 0.028) was a protective factor, whereas duration of LT (OR ¼ 1.02; 95% CI, 1.00-1.05, P ¼ 0.03) was associated with aggravation in the clinical course of UC after LT ( (Table 5) .
DISCUSSION
This study attempted to investigate the clinical course of UC after LT for PSC. Published studies on the natural course of IBD after LT demonstrated variable results. Furthermore, the methods by which UC activity is evaluated in studies differs, and this makes comparisons even more difficult. 25 Some of the similar studies included only a limited number of cases [25] [26] [27] 31, 33, [35] [36] [37] ; however, our study encompasses a large population of transplanted cases with a significant number of patients with PSC/ UC. Furthermore, in the present study, we compared the clinical course of UC before and after LT using 2 different scales: first was based on the needed changes in the UC medications before and after LT and the other according to a validated clinical disease activity scoring system.
A battery of studies concluded that patients with UC usually run a milder clinical course after LT. 26, 35, 36 Navaneethan et al 26 compared disease activity based on colonoscopic findings and the number of flares before and after LT. They found that approximately 82.8% of patients had quiescent UC after LT and only 8.6% experienced some aggravation in disease activity after transplantation. Accordingly, our study findings showed that most patients with PSC/UC had lower clinical colitis activity scores, and therefore, a milder clinical course after transplantation. Another study on a limited number of patients illustrated that UC severity was unchanged before and after LT in 67% of patients, worsened in 26.5%, and improved in 6.1%. 37 The investigators used a relatively similar but modified treatment requirement model for disease activity similar to the one that we adopted from Befeler et al. 35 In our study, there was a slight difference between those patients who experienced improvement and those with unchanged treatment before and after LT (45.4% versus 46.7%). Furthermore, just 12 (7.9%) patients had an aggressive course posttransplantation in our study. In the above-mentioned study, 37 they considered de novo IBD as an exacerbation in the course of UC. Similarly, some other studies that showed worse post-LT course of IBD included de novo IBD in their population, 25, 27, 31 and this lead to them having a greater percentage of cases with aggravated disease activity after LT. By contrast, we excluded patients with de novo IBD to maintain a much more homogeneous population for the comparison of disease course before and after transplantation. We suggest that de novo IBD and UC disease activity (recurrence) should be considered as discrete entities after LT, even in PSC. Its occurrence should not be considered as UC disease aggravation after transplantation. Furthermore, risk factors for UC disease activity and de novo IBD should be evaluated in separate studies.
There is a discrepancy between the results of the 2 different activity models used to evaluate UC activity. According to the simple clinical colitis activity index, the majority of patients (78.3%) showed improvement in their disease severity. However, using the treatment requirement model, much fewer patients (about 46%) showed improvement or no change in activity. We postulated that this discrepancy may be because physicians hesitate to attenuate treatment and stop 5-ASAs even if IBD is under control after LT. As a result, they recommend their patients to continue 5-ASAs in the same manner as before LT to avoid disease relapse. Therefore, we believe that the simple clinical colitis activity index would be a much more precise index for UC course assessment despite having some recall bias and being only patient dependent.
A recent study with a considerable sample size reported that IBD disease activity remained unchanged or improved in 60% of cases, whereas 40% of patients had some aggravation in their disease activity after LT. 43 In contrast to our study, which only included patients with UC with the onset before LT, they included all types of IBDs (UC, CD, and unclassified IBDs) and 11 patients with de novo IBD. The investigators concluded that combined use of MMF and tacrolimus (hazards ratio 3.9; 95% CI, 1.9-7.9, P ¼ 0.001) was a significant risk factor for disease severity after LT, whereas dual therapy with cyclosporine and azathioprine (OR 0.4; 95% CI, 0.2-0.9, P ¼ 0.043) was a protective factor. At the end, they recommended switching to cyclosporine and azathioprine as maintenance regimen in patients with PSC undergoing LT. In this study, they could not show whether the use of cyclosporine alone was protective. Although they showed that tacrolimus (OR 1.6; 95% CI, 1.0-2.6, P ¼ 0.05) alone was a significant risk factor for IBD worsening in univariate analyses, this could not be proved in the multivariate analyses. Few other studies have shown tacrolimus as a risk factor for recurrent IBD after LT including de novo IBD. 30, 34 In our study, although according to univariate analyses the use of MMF, combination of MMF and tacrolimus, and tacrolimus alone were shown to be significant risk factors for aggravated disease activity after LT, none of them remained statistically significant in the multivariate analyses (Tables 3  and 5 ). Interestingly, based on the 2 models used in our study, cyclosporine use after LT was a significant protective factor associated with a decrease in UC severity after LT. Both tacrolimus and cyclosporine are calcineurin inhibitors. It is still a matter of debate as to why the severity of IBD worsens with tacrolimus and improves with cyclosporine after LT in patients with PSC. One hypothesis states that tacrolimus may affect intestinal integrity and increase its permeability leading to bacterial translocations and endotoxemia. 2, 48, 49 Another hypothesis suggests that induction of T-cell apoptosis is important in the control of inflammation in patients with IBD. T-cell apoptosis is less prominent with tacrolimus than cyclosporine, therefore patients who are taking cyclosporine may experience less severe IBD courses. [49] [50] [51] An important issue is that some studies showed that tacrolimus use decreased the rate of rejections in the first year after LT much more than cyclosporine did. As a result, recommending the use of cyclosporine instead of tacrolimus after LT for patients with PSC/UC to avoid UC exacerbations after transplantation is not straightforward. 49, 52 Unlike 5-ASAs and azathioprine, which are considered beneficial for maintaining remission in IBD, steroids alone are not effective for this purpose. 27 Some studies have suggested a possible association between early steroid withdrawal and worsening in IBD activity after LT. 25, 32, 53 Papatheodoridis et al 25 demonstrated that UC severity increased in 50% of patients and did not improve in the remaining half of PSC cases when steroids were withdrawn within 6 months after LT. Another study illustrated that the use of steroids after LT reduced the risk of colectomy at prolonged follow-up. 26 In our study, we could not show that glucocorticoids are either protective or risk factors of worse disease activity after LT.
Few other risk factors have been suggested for IBD activity after LT in PSC cases. Smoking at the time of transplantation and subsequent cessation, 31 symptoms at the time of LT, short interval of IBD before LT, cytomegalovirus mismatch, 30 or acute cytomegalovirus infection 34 are among others. Our study showed the duration after LT as a risk factor of UC disease activity and pretransplant body weight as a protective factor. Body weight might be indirectly indicative of a much better health status or underlying disease control. This study could not show smoking as a positive or negative risk factor.
Despite other studies reporting higher rates of colectomy after LT, 26, 43 in the present study, only 2 patients (1.3%) underwent colectomy after LT due to colorectal cancer or dysplasia found in their surveillance post-LT colonoscopy. Because of our study design and very limited number of patients with colectomy, we could not evaluate probable risk factors of post-LT neoplasia.
The limitations of this study were the retrospective design and some recall bias in the simple clinical colitis activity score. We could not evaluate the number of flares, time of flares, and colonoscopic findings due to the lack of sufficient data.
In conclusion, our findings show that most cases with PSC/ UC have a milder course of IBD with less disease activity after LT. In patients with PSC/UC undergoing LT, cyclosporine use may be beneficial for IBD treatment.
